Nasdaq · Healthcare
Beam Therapeutics Inc. (BEAM)
As-reported financials and recent SEC filings for Beam Therapeutics Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$139.7M
Net income
$-80.0M
Net margin
-57.2%
Diluted EPS
$-0.81
ROE
-6.5%
P/E (TTM)
—
Market cap
$3.58B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $139.7M | $63.5M | $377.7M | $60.9M | $51.8M |
| Gross profit | — | — | — | — | — |
| Operating income | $-383.7M | $-415.6M | $-176.5M | $-338.5M | $-392.5M |
| Net income | $-80.0M | $-376.7M | $-132.5M | $-289.1M | $-370.6M |
| Diluted EPS | $-0.81 | $-4.58 | $-1.72 | $-4.13 | $-5.77 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-22
View on EDGAR →8-K2026-06-08
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →Go deeper on BEAM
Search Beam Therapeutics Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.